Article citationsMore>>
Tomita, Y., Shinohara, N., Yuasa, T., Fujimoto, H., Niwakawa, M., Mugiya, S., Miki, T., Uemura, H., Nonomura, N., Takahashi, M., Hasegawa, Y., Agata, N., Houk, B., Naito, S. and Akaza, H. (2010) Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma. Japanese Journal of Clinical Oncology, 40, 1166-1172.
http://dx.doi.org/10.1093/jjco/hyq146
has been cited by the following article:
-
TITLE:
Efficacy and Safety of Axitinib as First-Line Therapy in Japanese Patients with Metastatic Renal Cell Carcinoma
AUTHORS:
Takeshi Namekawa, Satoshi Fukasawa, Atsushi Komaru, Masayuki Kobayashi, Takayuki Ohzeki, Yosuke Sato, Junryo Rii, Hirotsugu Uemura, Tomohiko Ichikawa, Takeshi Ueda
KEYWORDS:
Axitinib, Renal Cell Carcinoma, First Line
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.6 No.8,
July
28,
2015
ABSTRACT: Previous study
reported that patients treated with axitinib as second-line therapy had longer
median progression-free survival than those treated with sorafenib for
metastatic renal cell carcinoma (mRCC). In this study, we reviewed our
experience of axitinib as a first-line therapy for mRCC in Japanese patients,
focusing on its efficacy and safety. We retrospectively assessed 26 patients
treated with axitinib as a first-line therapy for mRCC from July 2010 to July
2014 at Chiba Cancer Center and Kinki University Hospital. Observation period
was 24.6 ± 18.3 months. The objective response rate was 50.0%, and the median
progression-free survival was 27.5 months. Overall survival was not estimable.
Common grade 3 adverse events were hypertension in 19 patients and proteinuria
in 5 patients. Axitinib demonstrated significant efficacy as a first-line therapy
in Japanese patients with mRCC. Careful monitoring and management of the
adverse effects may help to control its toxicities.
Related Articles:
-
Du Thanh Hang, Than Thi Thanh Tra, Le Minh Tuan, Geoffrey Peter Savage
-
Ananda Prasad Panta, Ram Prasad Ghimire, Dinesh Panthi, Shankar Raj Pant
-
Minzhi Wei, Yujian Gan, Shengqiang Tang
-
M. M. Fall, E. H. M. Niang, C. D. Niang, B. Niang, A. K. Toure, B. Diatta
-
Takeshi Namekawa, Satoshi Fukasawa, Atsushi Komaru, Masayuki Kobayashi, Takayuki Ohzeki, Yosuke Sato, Junryo Rii, Hirotsugu Uemura, Tomohiko Ichikawa, Takeshi Ueda